This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and {HEAD ~ their use} as {TAIL ~ inhibitors} of the Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes 
as
This invention relates to aspartyl protease inhibitors , pharmaceutical compositions comprising said compounds , their use in the treatment of cardiovascular diseases , cognitive and neurodegenerative diseases , and { HEAD ~ their use } as { TAIL ~ inhibitors } of the Human Immunodeficiency Virus , plasmepsins , cathepsin D and protozoal enzymes
OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH HEAD HEAD HEAD HEAD HEAD HEAD REL TAIL TAIL TAIL TAIL TAIL OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH